Our vision is to be a leader in identifying, developing and commercializing novel drugs that address unmet needs of people with rare cancer conditions.
Learn more about us:
New Strong Orviglance Data Support Successful SPARKLE Completion with Substantially Fewer Patients
QUARTERLY REPORT Q3 2022: Successful completion of two out of three studies for regulatory submission
New market research shows strong support for Orviglance